Dissecting variability in responses to cancer chemotherapy through systems pharmacology

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 1, 2010, Pages 34-38

  Yang, R ^a   Niepel, M ^a   Mitchison, T K ^a   Sorger, P K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL LINE; CLINICAL PHARMACOLOGY; DRUG RESEARCH; GENOMICS; GENOTYPE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SYSTEMS PHARMACOLOGY; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; ENVIRONMENT; HUMANS; NEOPLASMS; PHARMACOLOGY, CLINICAL; SYSTEMS BIOLOGY;

EID: 77953809368     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.96     Document Type: Review

References (44)

1. Potti, A. & Nevins, J.R. Utilization of genomic signatures to direct use of primary chemotherapy. Curr. Opin. Genet. Dev. 18, 62-67 (2008).
2. Stadler, Z.K. & Come, S.E. Review of gene-expression profling and its clinical use in breast cancer. Crit. Rev. Oncol. Hematol. 69, 1-11 (2009).
3. Zhou, S.F. et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab. 9, 738-784 (2008).
4. Edwards, S.L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008).
5. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to geftinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306-13311 (2004).
6. Condeelis, J. & Segall, J.E. Intravital imaging of cell movement in tumours. Nat. Rev. Cancer 3, 921-930 (2003).
7. Lin, K.y., Maricevich, M., Bardeesy, N., Weissleder, R. & Mahmood, U. In vivo quantitative microvasculature phenotype imaging of healthy and malignant tissues using a fber-optic confocal laser microprobe. Transl. Oncol. 1, 84-94 (2008).
8. National Cancer Institute Developmental Therapeutics Program. Synthetics: First Diversity Set Information http://dtp.nci.nih.gov/branches/btb/ivclsp. html.
9. Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med. 2, e313 (2005).
10. Chakravarti, A., Loefer, J.S. & Dyson, N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62, 200-207 (2002).
11. Turke, A.B. et al. Preexistence and clonal selection of MET amplifcation in EGFR mutant NSCLC. Cancer Cell 17, 77-88 (2010).
12. Network, T.R. Comprehensive genomic characterization defnes human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
13. Chin, K. et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529-541 (2006).
14. Neve, R.M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
15. Dobson, P.D. & Kell, D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Discov. 7, 205-220 (2008).
16. Szakács, G. et al. Predicting drug sensitivity and resistance: profling ABC transporter genes in cancer cells. Cancer Cell 6, 129-137 (2004).
17. Gottesman, M.M., Fojo, T. & Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002).
18. Henrich, C.J. et al. A high-throughput cell-based assay for inhibitors of ABCG2 activity. J. Biomol. Screen. 11, 176-183 (2006).
19. Raghavan, A.S. & Hang, H.C. Seeing small molecules in action with bioorthogonal chemistry. Drug Discov. Today 14, 178-184 (2009).
20. Sung, J.H., Kam, C. & Shuler, M.L. A microfuidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10, 446-455 (2010).
21. Sergina, N.V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441 (2007).
22. Deininger, M., Buchdunger, E. & Druker, B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653 (2005).
23. Tsao, M.S. et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
24. Shibata, T. et al. Genetic classifcation of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin. Cancer Res. 11, 6177-6185 (2005).
25. Kitano, H. Systems biology: a brief overview. Science 295, 1662-1664 (2002).
26. Schoeberl, B. et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2, ra31 (2009).
27. Zhu, y., Ghosh, P., Charnay, P., Burns, D.K. & Parada, L.F. Neurofbromas in NF1: Schwann cell origin and role of tumor environment. Science 296, 920-922 (2002).
28. Meads, M.B., Gatenby, R.A. & Dalton, W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9, 665-674 (2009).
29. Pickl, M. & Ries, C.H. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28, 461-468 (2009).
30. Weigelt, B., Lo, A.T., Park, C.C., Gray, J.W. & Bissell, M.J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res. Treat. (2009); e-pub ahead of print 22 August 2009.
31. Koschny, R., Walczak, H. & Ganten, T.M. The promise of TRAIL-potential and risks of a novel anticancer therapy. J. Mol. Med. 85, 923-935 (2007).
32. Khademhosseini, A., Langer, R., Borenstein, J. & Vacanti, J.P. Microscale technologies for tissue engineering and biology. Proc. Natl. Acad. Sci. U.S.A. 103, 2480-2487 (2006).
33. Flaim, C.J., Chien, S. & Bhatia, S.N. An extracellular matrix microarray for probing cellular diferentiation. Nat. Methods 2, 119-125 (2005).
34. Saez-Rodriguez, J. et al. Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. Mol. Syst. Biol. 5, 331 (2009).
35. Elowitz, M.B., Levine, A.J., Siggia, E.D. & Swain, P.S. Stochastic gene expression in a single cell. Science 297, 1183-1186 (2002).
36. Dunlop, M.J., Cox, R.S. 3rd, Levine, J.H., Murray, R.M. & Elowitz, M.B. Regulatory activity revealed by dynamic correlations in gene expression noise. Nat. Genet. 40, 1493-1498 (2008).
37. Raj, A., Peskin, C.S., Tranchina, D., Vargas, D.y. & Tyagi, S. Stochastic mRNA synthesis in mammalian cells. PLoS Biol. 4, e309 (2006).
38. Spencer, S.L., Gaudet, S., Albeck, J.G., Burke, J.M. & Sorger, P.K. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459, 428-432 (2009).
39. Rosenfeld, N., young, J.W., Alon, U., Swain, P.S. & Elowitz, M.B. Gene regulation at the single-cell level. Science 307, 1962-1965 (2005).
40. Niepel, M., Spencer, S.L. & Sorger, P.K. Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr. Opin. Chem. Biol. 13, 556-561 (2009).
41. Reya, T., Morrison, S.J., Clarke, M.F. & Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
42. Visvader, J.E. & Lindeman, G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
43. Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
44. Bell, D.W. et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 37, 1315-1316 (2005).